let has operations it, has busy given reiterate Thank thus you, speaking for COVID-XX which pandemic far. an I how appreciate of call proud conference and we that the during to way the have at the I move affected would position expected later in everyone, today. the their world full earnings to ongoing I this first update an the adapted and on us our launch different time, start the in like season, joining Volition’s of especially call with we with us pandemic, whole excellent ourselves for efforts Volition am fantastic this how team towards our first as put kept on speed working year. find products
the where contingency with of During and quarter protect well-being planning employees, first the possible. implemented our remotely we working employees of health XXXX, to most
remote observing foot square thus in dedicated Belgium However, social site our our the facility. addition technicians, distancing, attendance remained in other our efforts, has lab open our large verticals our to in far and with lab of XX,XXX
indeterminate key utilizing the of continue and the it the towards moving two second indeed to products, to As quarter like our for keep looks platform. we into try on Nu.Q lockdown could allow mitigate cutting our to areas focused pandemic and continued first the edge future, the effects us
pandemic. to launch strategy on concurrently, product where our we much work programs and program and to More have position launch during many capital cash offering our possible to and stock underwritten our Firstly, and of offering the common balance for we’ve through our stock sheet both of common At very of our The an importantly, strengthened sale significantly existing public Market pursuant ensure products strengthened the later. sufficient and shares
manufacturing those through our Silver in addition purchase of the known a materials Secondly, supply a have components neighboring future Belgium key and this all end, in offer as bringing to One. announce we’re to happy I’m increased by just second our in-house. materials submitted an To for very today the have facility supply ourselves we flexibility looking to the chain of we of key products
and components reagent secure this revenue purchase products the be will Octamer more a our cost We to supply year, this at own expect our that to less of of on lower or drive well. hub both building our as production earlier all and of later
And We out and with at in $XX quarter cash second start the last financials. important compared quarter, quarter. million equivalents closed I the March end million $XX.X strengthened all the will so with cash with of the
to second the especially this, proceeds In pleasing, public addition posed by the raised stock quarter during an of which pandemic in we the XXXX, volatile million was given underwritten in challenges gross the market. $XX.X and offering,
and through & their launching common raised use had Rule further subsequent to additional, We been throughout sold offering the gross through the times next proceeds an an our few for pursuant thank to would Market of XXXX of periodically The our $X.X and also several $XX end, I stock, statement equity Through to in to along of end offer strong ATM as existing raised August we disclosed quarter, ATM. like our price products the registration agent shares our Oppenheimer sale for time our pandemic the our our At the we having late the sheet again support or to support. approximately acting XXXX to decided now under XXbX-X the previously million by offering our time stock And provides goal plan. The quarter common strengthen aggregate in to uncertain balance we proceeds million has X, from the $X.X quarters. up since over in caused during quarter investors the Co., under During gross million the our with of ATM program, place yet of and of approximately principal. ATM. the ATM, second and/or
was offering May as investors some as we existing completed many underwritten ones. And new in well public oversubscribed. we Our that welcomed
and for June our a delighted in added to also We’re forward is Indexes to the Russell XXXX be great company. step Russell Microcap
the us pandemic. say I it activity a and all continued during achieve to milestones our strengthened position, flexibility providing to think great significantly this many cash fair is runway our give
towards rate actual announced results succeed novel prognostic that expect to launching not commercial to to of body’s approximately it evaluation in targeting our than And our other in up COVID-XX, I’m for itself. products We that only concept this launches. to yet test, the approach launch two resources from our pneumonia. filed additional a development, our it proof response wide we we very I’ll $X.X July, we within the the through range for helpful test continue regarding proud to also in clinical clinical very burn $X.X The immune years to of assay of picked had come against development the we had only both was triaged by increase measures rather expect just facilities product million could assays which work of incredibly achievements June Since patent as a we of and expenditures have per prove and multiple study potential COVID-XX much ago, securing many mainly some and we worldwide. outbreaks, month, the samples useful is due the quarter. Indeed investment and go and of the quarter in carefully. a but reported studies. respiratory a could manage when months of people we including date. virus commercialization, viral test. acceleration be a If million has continue make few It purchase influenza as April, to our fight we this of the done to in started, of we
And XX.X% Just that immunoassays of single to with recap, found positive an results elevated PCR the positive that assay COVID cohorts accuracy subjects, XXX% in second the nucleosomes date, the May also healthy were control nucleosomes preliminary of controlled of patients with nucleosome reported curve increased subjects. disease the and relative assay more XX.X%. demonstrated we with citrullinated two have and To in And quantitative histone sensitivity severity. with both showed an accuracy, tested XX% now variant plasma AUC, for study Nu.Q with independent X.X to specificity. results area and severe COVID-XX under promising patients importantly, versus highly
artificial in or levels found oxygenation, as guiding positive that the believe disease were patients COVID-XX serve nucleosomes extracorporeal we that requiring a ventilation for biomarker nucleosomes highest severity strong could Nu.Q that patients. a Given the in potential would completion have COVID-XX studies larger, data support to prognostic launch. product now needed imply longitudinal we be focused so of and on that are of potential, These could
care data peer-review we tested would positive in a the enable this believe We still deteriorate need this resources for to need to both Early pandemic. and of very look an identification unmet are impact and and for submitted healthcare likely have outcomes fighting care publication. of much critical collaborators critical for the more efficient patients improved providers. is of worldwide use triaging forward the who most its for Our patients and COVID-XX
am many disease, to test on who of applications year. response by appears that COVID-XX pleased Our insight prognostic extremely critical higher bodes in COVID cells power. and involving the doctors of the very and also and likely which it as Munich massive in pneumonia, those blood versus and of tests serious the work help of of specific This and to symptoms. remains it including to platform And goal I to hyper-inflammatory be I have may is future influenza can and our Liege test the pneumonia cancer make testament robustness our be provide NETs biomarker I Nu.Q current range do COVID, visibility may into performed also care to disease extremely virus lab for is spent their platform and while many lab patients to develop own injection these with independently strain Nu.Q It are to again, focus. the market. influenza it diagnostic has am for worldwide hopeful nucleosomes believe Nu.Q Consequently, clear should the kit helpful tests for or in and versatility optimizing. potential likely hospitalization positive core are toolbox that by patients in years respiratory our their patients which nucleosomes any kits lungs products every also Nu.Q the increase equipment. like potential test team I of the damage works ongoing up very made levels results less not. a believe blood used other early the and that to teams if use epigenetic the are in the resources, require a Nu.Q also our pandemic. that leveraged the influenza well viral would well setting. which demonstrate we These help given that massive monitoring including well develop of yet white outbreaks our into particularly to that the and for
et diagnostic, moved pharmaceutical many world, fairly slowly. cetera, As know, you of the healthcare
particularly And this groundwork grateful studies most quickly to team I’m so preparing longitudinal underway get who on in so our and studies, quarter. have and worked so indeed these collaborators, and importantly, the to our diligently in for
to In product designed contract we prognostic perspective, an terms it’s completion, of all longer launching be a conduct satisfy no for COVID-XX to If to requirements in to study requirements apply EUA discussions Use an The is will are currently with application. Emergency large a U.S., XXX(k) in Authorization, de research all to traditional satisfy EUA. a FDA novo also FDA submit study. study organization major option intended a upon U.S. COVID-XX the
Authority, Biomedical EUA to funding Advanced maximize the These this and of Preparedness of the of receiving approvals, to positive study distribution the be Operation Research results Epidemic be programs CEPI. study were will only designed to OWS, Development our to ordered the awards In received Innovations, funding regulatory receiving for accelerate likelihood Warp can and and proceed Speed, and/or Coalition addition product that COVID-XX from manufacturing, BARDA, patients. If development, are products. the COVID-XX
Use in term Authorization other expand via a post-market to studies used clinical longer the product XXX(k) However, Emergency uses. EUA, to be many commercialize can
filed resources. claims For in hyperimmune for XXX(k) example, could be also to reactions influenza. XXX(k) plus filed, use be associated infectious for subsequent subsequently intended and use COVID-XX will use a for diseases example, broadly with More
first So approval. longitudinal hope see as as study I we being other of COVID-XX to details step. in Mark to would a represent this to announcing continue further Europe study look this European great can. also in planned soon I CE announce this low in forward aim to a we details If currently positive product results studies available look as further soon for soon platforms also Mark we a studies, cost that year. at used worldwide, longitudinal CE soon multiple Asia to we’re end these after product of in launch any on beginning possible And we looking to laboratory have as Europe. could And the thereafter. be launch of
despite as key has to the in various slow COVID both communication issues. of the direct we a but the we is for of XX all another to in have to lockdown or pandemic, in assay These to an assays and our XX of COVID either now collection, platform, is our by June contending Triage standard study the the the make offsite, IRB help expect program the developed to those earlier. We have approved think participant chain our and continued reached. update, samples, control. From view, personalized recombinant study cancer degrees four will institutions of We’ve that pandemic. not ways are or we affected we do limits example. paused system used assays is progress work veterinary our by clinical in that enrollment, XX cancer are triage. say hard also be during the have the in month. programs, but home that and reopening, potential I diagnostic discussed trials exposure facing it lot particularly development reach our meets our development nucleosomes useful the therapy companies supply obviously in three fair successfully the trials, U.S. it various a to areas market running other restrictions, perspective, of this target a of these and or manufactured in and work This large to biotech will Marquee The been also and by completed control COVID-XX assay managed now Australia assays be we host you at being recently for research our that with our for of with which our June the again, total programs. add assay our the that be under remote, use We’ve such initially development impacted U.S. strong tested to care be beyond our is the have step COVID-XX of as of our only now this recommitted say track been we Further in-house and believe pharma key year. our also vet seeking travel could regions many to date monitoring may development, product begin additional this as none milestones, used are numbers. progress on and be great for and and conditions. last we point delighted plan expected plan We through EDRN in that approach hurdles enhance sold has match something made and nucleosomes be both These XX in EDRN but sites the the other have this will milestone and this pandemic. to we us readouts restrictions of of are Most but huge of can restrictions. with have with our clinical research month as was but This the kept by medicines end end a by addition was used capacity, September. I’m yet are in on has And as milestone open that our full studies by issues now Australia pandemic thought In currently in-house, the continued been at most a programs, of and the or fewer to with Marquee assays further to outside sites of XX new enrolling collecting. despite barriers. From point And and is first this to
So in extended. originally in we that expect this trial and summary, may XXXX the slower EDRN collections than be planned expect
of the I completed and and University of those subset both Taiwan with to will collection Taiwan studies by of With we’re once complete National now collection we CRC at the next large always, continues available. with of scale year. details to As studies, update studies, our middle National further The data with eight lung, both regards analysis. have the the on University and two collaborators assays working on aim
We of expect to quarter over this coming number run additional assays.
trials. clinical by scratch, can filings the of by so developing submit from made third paper and This biomarker our the our we a new lung the where per of three Oncology for the end throughout though. papers used And just it now oral quarter more the at as in and published this to best view plan as Veterinary well. we APDW the of We’ll peer-reviewed year. Meeting Virtual finally, either October Clinical for data the with acceptance a Society we for Cancer Society at our then process in two can, and colorectal submit received a IASLC capture study abstracts colorectal in additional this a ASCO, or perspective, this aim have from of American from As spectrometry, for and non-Hodgkin’s that then Nu.Q of is in we held in studies, cancer well rigorous abstract key quarter, planning stages of are with also abstracts at a mass We conferences; just cancer space. January. clinical one ever including for to submitting lot publications be quarter Through processing as two the conferences, data cancer at some was December be but lymphoma, progress identifying fantastic our results have our the the clinical simply upcoming our plan the program one clinical results final in had lung of generate point presentations of
As colorectal the lung for publication. accepted paper-wise, Three showing pre-analytics platform. a cancer collaborators of submitted APDW for COVID-XX I abstracts pregnancy, and lung alluded review and and disease, again cancer our for for peer have for our wide underway Nu.Q to by are earlier, respectively. adaptability has Vet paper the yet Clinical using for been complications both submitted been IASLC, technology, during for papers and regarding
papers and summer more three have humans pre-analytic due program over process, also sequencing. for on We the spectrometry capture submission two a mass papers for the in paper and Nu.Q months for from
are with publish the future. comfortable and very space, moving collaborators’ are to work. that our very and to wide stable so we IP our Now ranging our robust we throughout platform, our this aggressively to continue and all Please
delighted the XX,XXX as that facility accepted science square hub service lab Silver the manufacturing announce I’m lab. call on a One purchase Firstly, box, will our and have today Belgium, to same our in an to on we offer foot be which
product and transactions, accepted of been our estate and cost has with and to cost development. loans full both comes least at previous newer be both that keeping parties down new million non-dilutive grants will the a supported showing the real the the anticipate these This now our moving are fit-out necessary as through commitment our facility of from to phase order We at Our regions. some costs of €XXX completing a paperwork. including
year. several be We that right place away months produce out and operational next October hope the next the will and ISO it key components certification over will we expect with the fit take in few
scale, Nu.Q antibodies we’ll full are finalized. products. branded at caliber such as elements large as indeed and to to our And that to our nucleosomes, which diagnostic manufacture recombinant act key in materials, addition is plan once raw Our assays, produce kits the
to expect all offer elements. We
purposes sale commercial and for Europe my beyond. both see and and sale for in products trial So clinical
would intend sample the earlier install which for an price such lab do as undertake a also service service mentioned pregnancy as call. We new a in I samples think the process names on external for parties, to facility, as
components only manufacturing securing our thereby facility that in-house, The of key bring not supply this other thing chain. new would
an COVID-XX of and We’re find recruiting the happier to to broadly, assay product, a of announcing a step cost we’re reduce Use Only products. service would our forward end, through or great that More road commercialization turn triage of an I development. and business exciting that we so appointment cancer lung, It’s of look one could situated soon. time be products. suitable closely also in lab. our current of elements forward to mark any Research manager reduce could production diverse stream. CE in not help Kits and these I’ll colorectal our cancers, cost development revenue significantly through our to of as and drive we sales triage test It’s To the site that the revenue approach through propositions be another
of We quickly we effectively. have can and a licensing discussions to cost the platform with range permits companies market providers and supply ensure
was Our due June the first to several from in few triage our put be is quarantine. to Being due being weeks. completed as CE delayed late halted facility COVID-XX next members mark on suppliers key
control. new we Given under direct us giving greater in-house in-house capabilities, flexibility, work funnel have brought our our now and the
best for be additional cancers, get like products to benefit and where made The first you in then forward and for in-house product remission later inventing the having game read have during is year. chance great diversity pet and other This option. wise, the launch products we blood itself track on production the one If the to of of Product we product focus monitoring, uses, We market strides we at launched of launching shows, to best pandemic. this remission defend I’d end next monitoring to despite that you of and due target XXXX. this the feel our on aim has remain the the our invest year. Nu.Q an the supply pandemic.
websites commercialization data our Nate serve presented. to presentation formerly Vet Commercialization Nu.Q been oral expect with meeting, for additional and accepted I will line CEO Chief Vet at In focus Volition two VCS purely the product we Officer. earlier, Dewsbury focus be as his where said As have further shift
side area vet of truly on quickly the work and proud business could closely. watch not the is be progress the whole this to to fantastic how of the of has time. an I impact team hot made have difficult continued We business, families and of the felt the throughout adapting this Thanks collaborators and our their has the been normal. say pandemic to new throughout My world. for also The thanks to everywhere. them to suppliers
grateful also attitude. we financial can go to I for are their thank community should do investors. so And out the our and
We have appreciate and our and order our your sheet future product. to our have greatly significantly support first balance strengthened milestones in deliver
I Nu.Q future, with these our coming would the and progress at epigenetics of an in been and to founding since very to our This to mission it’s is and vision human advantages our on health. like and heart the reiterate epigenetics epigenetics. company of exploiting Looking the animal what and focused makes excited fruition with advancing us has so our our platform Volition space. science our
last extremely on with milestones key the our Volition say detect if decade our field. than work property, we believe incredibly strong fronts, a of in in have throughout Overall, making, is epigenetic both chromosome. team animals. and of us the player team this and the the We So, field. In in with opportunities. at We significant it’s the in to the intellectual I’m position more our developed we the expanding human a important aim several expensive is our including future not DNA, ever ability full excited I not be with to beyond an Nu.Q’s company’s epigenetics cancers key as, so this and and am progress this many short, ever-growing range epigenetics, whole puts genetic in to excited with DNA. portfolio delighted it’s team by by we’re Indeed momentum report IP year
on and data Capture to COVID-XX relating clinical in triage the data NU.Q development. to test the addition In the
driving during also key in pandemic on will quarters the where coming We our focus revenue the four in areas. possible
year of reagent potential the the the tests; four with Board facility forward look revenue; sharing earnings Thanks coming drive production company, season. pandemic, the and with Vet yet. results along key be and to commercialize. I, and four; our technology our the the I year for appreciate our to most our call for the of over new given the we others platform. using products; the sales optimized our thirdly, secondly joining and Despite of XXXX licensing studies very it, expect much indeed busy rest months exciting call Firstly, today. to whole to triage our
take to now Operator? We your question. are happy
